myPOS Opens First Flagship Store in Paris
Europe's fastest growing payment solutions provider, opens a store in Paris. This is the 7th European store for the company, aiming to strengthen its physical presence and getting closer to its customers in France.
Since its launch in 2014, myPOS has been helping SMEs grow through payments technology. Not only it provides a range of multifunctional POS terminals at super-affordable prices (from € 29 to only € 349), but also enables every merchant with a free multi-currency account into which all card payments are settled immediately, at no extra cost.
“myPOS is the first and only payment solution to provide instant pay-out to the merchant account. Before myPOS, business owners had to wait for days and weeks to access their money.’’ – says Christo Georgiev, founder of myPOS – ‘’We hope that French businesses will take advantage and improve their business operations with myPOS, resulting in positive cashflows’’.
The myPOS devices read chip & pin, magnetic stripe and contactless cards, and accept popular card operators such as VISA, Mastercard, American Express, JCB, Union Pay, plus European payment schemes such as Bancontact and iDEAL. Mobile wallets are welcomed too - Apple Pay, Google Pay and Samsung Pay.
myPOS is quickly gaining a foothold in Europe covering 30+ countries, having gained the trust of more than 80,000 clients.
One of the factors to this success is also the opening of series of flagship stores across Europe, something no other European payments provider has done yet, starting with London, Amsterdam, Sofia, Milan and Barcelona in 2018, and adding Antwerp and Paris in 2019, with more to come.
In February 2019, the Berlin Merchants Payments Ecosystem jury awarded myPOS the Best POS Innovation Award. Later this year, myPOS was also nominated by the European Business Awards for the Award for Innovation and by the 2019 Payment Awards for Best Merchant Acquirer/Processor.
About myPOS World Ltd
myPOS World Ltd is a fintech company operating the myPOS platform across Europe. The myPOS e-money accounts and payment services are provided by a myPOS-owned UK E- Money Institution, authorised and regulated by the FCA and by an associated EU-licensed E- Money Institution, a direct member of MasterCard, VISA, Amex, JCB, UnionPay and other card schemes.
myPOS headquarters is at Level 24, The Shard, London Bridge Street, London SE1 9SG, UK.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005043/en/
Contact information
Irina Stefanova, PR manager
Email: pr@mypos.com
Telephone: +44 20 3129 3086
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 11:00:00 EET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 10:00:00 EET | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106888864/en/ Photo credit
Red Hat Introduces Confirmed Sovereign Support for European Union6.11.2025 10:00:00 EET | Press release
Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations. More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain transparency, jurisdictional security, compliance and autonomy. Red Hat Confirmed Sovereign Support is designed to add
Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 10:00:00 EET | Press release
Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition journeys, they’re navigating a new wave of complexity from AI integration to the accelerating need for digitalisation,” said Jim Madej, President and CEO of Trilliant. “Meeting these goals requires solutions th
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA ® (ustekinumab) in Europe6.11.2025 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom